In the latest trading session,, 0.55 million Verona Pharma Plc ADR (NASDAQ:VRNA) shares changed hands as the company’s beta touched 0.38. With the company’s most recent per share price at $48.85 changed hands at -$5.32 or -9.81% at last look, the market valuation stands at $4.13B. VRNA’s current price is a discount, trading about -44.11% off its 52-week high of $70.40. The share price had its 52-week low at $11.39, which suggests the last value was 76.68% up since then. When we look at Verona Pharma Plc ADR’s average trading volume, we note the 10-day average is 1.61 million shares, with the 3-month average coming to 1.45 million.
Analysts gave the Verona Pharma Plc ADR (VRNA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended VRNA as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Verona Pharma Plc ADR’s EPS for the current quarter is expected to be -0.03.
Verona Pharma Plc ADR (NASDAQ:VRNA) trade information
Instantly VRNA was in red as seen in intraday trades today. With action -18.97%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 5.20%, with the 5-day performance at -18.97% in the red. However, in the 30-day time frame, Verona Pharma Plc ADR (NASDAQ:VRNA) is -22.08% down. Looking at the short shares, we see there were 9.85 million shares sold at short interest cover period of 6.25 days.
The consensus price target for the stock as assigned by Wall Street analysts is 75, meaning bulls need an upside of 34.87% from its recent market value. According to analyst projections, VRNA’s forecast low is 74 with 83 as the target high. To hit the forecast high, the stock’s price needs a -69.91% plunge from its current level, while the stock would need to soar -51.48% for it to hit the projected low.
Verona Pharma Plc ADR (VRNA) estimates and forecasts
Year-over-year growth is forecast to reach 626.15% up from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of 41.47M. 8 analysts are of the opinion that Verona Pharma Plc ADR’s revenue for the current quarter will be 53.02M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 7.21%. The 2025 estimates are for Verona Pharma Plc ADR earnings to increase by 128.70%.
Verona Pharma Plc ADR (NASDAQ:VRNA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 35.16% of Verona Pharma Plc ADR shares while 85.71% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 132.19%. There are 85.71% institutions holding the Verona Pharma Plc ADR stock share, with RA CAPITAL MANAGEMENT, L.P. the top institutional holder. As of 2024-06-30, the company held 1.1775% of the shares, roughly 7.63 million VRNA shares worth $110.37 million.
PRICE T ROWE ASSOCIATES INC /MD/ holds the second largest percentage of outstanding shares, with 1.1762% or 0.95 million shares worth $13.73 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were MUTUAL FUND SERIES TRUST-Eventide Gilead Fund and MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund . With 1.89 shares estimated at $92.4 million under it, the former controlled 2.22% of total outstanding shares. On the other hand, MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund held about 1.45% of the shares, roughly 1.23 shares worth around $60.15 million.
